ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025
Rhea-AI Summary
ImmuCell (Nasdaq: ICCC) reported unaudited results for the quarter ended September 30, 2025. Q3 product sales fell 8% to $5.5M, while nine-month product sales rose 7% to $20.0M and twelve-month sales rose 16% to $27.8M. The company posted net income of $1.8M for the nine months versus a loss of $2.7M year-ago, driven by higher sales and margin recovery.
Gross margin improved to 42.6% for the nine months (vs. 27.3% prior year). Adjusted EBITDA was $751k for Q3 and $4.42M for nine months. Balance sheet highlights: cash $3.9M, net working capital $12.8M, stockholders' equity $29.8M. Re-Tain remains in investigational use with Michigan State University while management addresses prior backlog.
Positive
- Nine-month net income of $1.8M versus a $2.7M loss prior year
- Gross margin recovered to 42.6% for the nine months (from 27.3%)
- Adjusted EBITDA improved to $4.42M for the nine months
- Twelve-month product sales increased 16% to $27.8M
Negative
- Q3 product sales declined 8% to $5.5M
- Q3 net loss of $0.14M (loss per share $0.02)
- Prior production backlog created difficult year‑over‑year quarterly comparisons
- Re-Tain remains in investigational use with no commercial approval disclosed
News Market Reaction
On the day this news was published, ICCC declined 1.31%, reflecting a mild negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $660K from the company's valuation, bringing the market cap to $50M at that time. Trading volume was very high at 3.0x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2025.
Product Sales Highlights:
- During the third quarter of 2025, product sales decreased by
8% to approximately$5.5 million compared to the third quarter of 2024. - During the nine-month period ended September 30, 2025, product sales increased by
7% to approximately$20.0 million compared to the nine-month period ended September 30, 2024. - During the twelve-month period ended September 30, 2025, product sales increased by
16% to approximately$27.8 million compared to the twelve-month period ended September 30, 2024.
Preliminary, unaudited product sales for the third quarter of 2025 were first reported on October 7, 2025. There are no changes to those figures.
Management’s Discussion:
“Net Income for the nine-month period ended September 30, 2025 was
“The Company has overcome a prolonged order backlog situation that arose from previous interruptions in production. As we can see in the quarter ended September 30, 2025 results, backlog dynamics have created difficult conditions for year over year sales comparisons,” added Mr. Fiori. “We now have sufficient inventory on hand throughout the supply chain to give our customers, distributor partners and sales team the confidence to drive product adoption and revenue growth. We are operating from a clean slate.”
“Another healthy sign is the recovery of our gross margin percentage. We achieved
“On the topic of Re-Tain®,” Mr. Fiori further commented, “our Investigational Product use of Re-Tain® is under way, in partnership with Michigan State University. We will continue to collect market feedback about product performance in the field over the remainder of 2025 and into 2026.”
Certain Other Financial Results:
- Gross margin was
43% and26% of product sales during the three-month periods ended September 30, 2025 and 2024, respectively. - Net loss was approximately (
$140,000) , or ($0.02) per basic share, during the three-month period ended September 30, 2025, in comparison to a net loss of ($702,000) , or ($0.09) per basic share, during the three-month period ended September 30, 2024. - Net income was
$1.8 million , or$0.20 per diluted share, during the nine-month period ended September 30, 2025, in contrast to a net loss of ($2.7) million , or ($0.34) per basic share, during the nine-month period ended September 30, 2024. - Adjusted EBITDA (a non-GAAP financial measure described below in this press release) improved to approximately
$751,000 and$4.4 million during the three-month and nine-month periods ended September 30, 2025, respectively, versus$196,000 and$35,000 for the comparable periods in 2024.
Balance Sheet Data as of September 30, 2025:
- Cash and cash equivalents increased to approximately
$3.9 million as of September 30, 2025 from$3.8 million as of December 31, 2024, with no draw outstanding on the available$1 million line of credit as of these dates. - Net working capital increased to approximately
$12.8 million as of September 30, 2025 from$10.6 million as of December 31, 2024. - Stockholders’ equity increased to approximately
$29.8 million as of September 30, 2025 from$27.5 million as of December 31, 2024.
Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):
This Press Release and the statements to be made in the related conference call referenced herein contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans, goals and strategies for our business; projections of future financial or operational performance; the timing and outcome of pending or anticipated applications for regulatory approvals and pending or anticipated regulatory inspections of our facilities and those of our contract manufacturers; future demand for our products; future adoption of Re-Tain® by dairy producers; growth in acceptance of our First Defense® product line by dairy and beef producers; future costs of product development efforts; the adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships to meet demand for our products on a timely basis; the impacts of backlogs on customer relationships; the efficacy of our contamination remediation efforts; whether or not we will experience future contamination events; the anticipated costs of (or time to complete) planned expansions of our manufacturing facilities and the adequacy of our funds available for these projects; the robustness of our manufacturing processes to meet future demand and related technical issues; future changes in our manufacturing capabilities and efficiencies; and any other statements that are not historical facts. These statements are intended to provide management's current expectation of future events as of the date of this earnings release, are based on management's estimates, projections, beliefs and assumptions as of the date hereof; and are not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties relating to: difficulties or delays in development, testing, regulatory approval, production and marketing of our products (including the First Defense® product line and Re-Tain®), competition within our anticipated product markets, customer acceptance of our new and existing products, product performance, alignment between our manufacturing resources and product demand (including the consequences of backlogs), adverse impacts of supply chain disruptions on our operations and customer and supplier relationships, commercial and operational risks relating to our current and planned expansion of production capacity, our ability to obtain colostrum that meets our specifications, and other risks and uncertainties detailed from time to time in filings we make with the SEC, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and uncertainties and are based on our current expectations, but actual results may differ materially due to various factors. In addition, there can be no assurance that future risks, uncertainties or developments affecting us will be those that we anticipate. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Statements of Operations (Unaudited)
| During the Three-Month Periods Ended September 30, | During the Nine-Month Periods Ended September 30, | ||||||||||||||
| (In thousands, except per share amounts) | 2025 | 2024 | 2025 | 2024 | |||||||||||
| Product sales | $ | 5,506 | $ | 6,012 | $ | 20,018 | $ | 18,742 | |||||||
| Costs of goods sold | 3,143 | 4,428 | 11,483 | 13,633 | |||||||||||
| Gross margin | 2,363 | 1,584 | 8,535 | 5,109 | |||||||||||
| Sales and marketing expenses | 919 | 844 | 2,472 | 2,630 | |||||||||||
| Product development expenses | 694 | 786 | 2,283 | 3,079 | |||||||||||
| Administrative expenses | 729 | 528 | 2,073 | 1,662 | |||||||||||
| Operating expenses | 2,343 | 2,158 | 6,828 | 7,371 | |||||||||||
| NET OPERATING INCOME (LOSS) | 20 | (575 | ) | 1,707 | (2,262 | ) | |||||||||
| Other (expenses) income, net | (155 | ) | (125 | ) | 110 | (406 | ) | ||||||||
| (LOSS) INCOME BEFORE INCOME TAXES | (135 | ) | (700 | ) | 1,817 | (2,667 | ) | ||||||||
| Income tax expense | 4 | 1 | 8 | 4 | |||||||||||
| NET (LOSS) INCOME | $ | (140 | ) | $ | (702 | ) | $ | 1,809 | $ | (2,671 | ) | ||||
| Basic weighted average common shares outstanding | 9,046 | 8,164 | 9,019 | 7,908 | |||||||||||
| Basic net (loss) income per share | $ | (0.02 | ) | $ | (0.09 | ) | $ | 0.20 | $ | (0.34 | ) | ||||
| Diluted weighted average common shares outstanding | 9,046 | 8,164 | 9,019 | 7,908 | |||||||||||
| Diluted net (loss) income per share | $ | (0.02 | ) | $ | (0.09 | ) | $ | 0.20 | $ | (0.34 | ) | ||||
Selected Balance Sheet Data (In thousands) (Unaudited)
| As of September 30, 2025 | As of December 31, 2024 | |||||
Cash and cash equivalents | $ | 3,886 | $ | 3,758 | ||
| Net working capital | 12,827 | 10,631 | ||||
| Stockholders’ equity | 29,801 | 27,518 | ||||
| Total assets | $ | 45,730 | $ | 45,100 | ||
Non-GAAP Financial Measures:
Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flow that either excludes or includes amounts that are not normally included in or excluded from the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP measures included in this press release should be considered in addition to, and not as a substitute for or superior to, the comparable measure prepared in accordance with GAAP. We believe that considering the non-GAAP measure of Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) assists management and investors by looking at our performance across reporting periods on a consistent basis excluding certain charges from our reported net (loss) income. Adjusted EBITDA is calculated and reconciled to the most comparable GAAP financial measure in the following table:
| During the Three-Month Periods Ended September 30, | During the Nine-Month Periods Ended September 30, | |||||||||||||
| (In thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||
| Net (loss) income | $ | (140 | ) | $ | (702 | ) | $ | 1,809 | $ | (2,671 | ) | |||
| Income tax expense | 4 | 1 | 8 | 4 | ||||||||||
| Interest expense (excluding debt issuance and debt discount costs) | 105 | 133 | 336 | 401 | ||||||||||
| Depreciation | 674 | 670 | 2,009 | 1,999 | ||||||||||
| Amortization (including debt issuance and debt discount costs) | 34 | 16 | 66 | 46 | ||||||||||
| Stock-based compensation expense | 73 | 78 | 192 | 257 | ||||||||||
| Adjusted EBITDA | $ | 751 | $ | 196 | $ | 4,420 | $ | 35 | ||||||
Cash payments to satisfy debt repayment obligations and to make capital expenditure investments are other uses of cash that are not included in the calculation of EBITDA, which management also considers when assessing its cash flows.
Conference Call:
The Company is planning to host a conference call on Friday, November 14, 2025 at 9:00 AM ET to discuss the unaudited financial results for the quarter ended September 30, 2025. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international). A teleconference replay of the call will be available until November 21, 2025 at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #7664668. Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business and is available under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company. An updated version of the slide deck was made available after the market closed on Thursday, November 13, 2025.
About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
| Contacts: | Olivier te Boekhorst, President and CEO |
| Timothy C. Fiori, Chief Financial Officer | |
| ImmuCell Corporation | |
| (207) 878-2770 | |
| Joe Diaz, Robert Blum and Joe Dorame | |
| Lytham Partners, LLC | |
| (602) 889-9700 | |
| iccc@lythampartners.com |
FAQ
What were ImmuCell (ICCC) product sales for Q3 2025?
How did ImmuCell (ICCC) perform year-to-date through September 30, 2025?
What margin and EBITDA improvements did ImmuCell (ICCC) report for 2025 YTD?
Does ImmuCell (ICCC) have approved commercial sales for Re-Tain as of Nov 13, 2025?
What balance sheet figures did ImmuCell (ICCC) report as of Sept 30, 2025?
When is ImmuCell (ICCC) hosting the conference call to discuss Q3 2025 results?
